SMT, Hybrigenics Form Research and Development Partnership

Small Molecule Therapeutics, Inc. (SMT) and Hybrigenics signed a collaborative research and development agreement. The goal of the partnership is to accelerate validation of lead compounds that can be developed into therapeutics for infectious diseases. SMT and Hybrigenics will partner any potential drugs arising from their collaboration with pharmaceutical companies for development. Financial terms were not disclosed.

Hybrigenics will provide Small Molecule Therapeutics with validated targets derived from protein interaction maps. These targets may be useful for the detection, prevention and treatment of infectious diseases and disorders. SMT will then screen these targets utilizing its proprietary technologies for drug discovery. Lead compounds will be further validated in Hybrigenics' proprietary modeling systems.

Small Molecule Therapeutics is a privately held biotechnology company.

Hybrigenics is a private Paris-based functional proteomics company.

For more information: Prabhavathi Fernandes, Chief Executive Officer, Small Molecule Therapeutics, Inc., 11 Dear Park Drive, Suite 116, Monmouth Junction, NJ 08852. Ph: 732-274-2882. Fax: 732-274-0086. fernandes@smtherapeutics.com.